Fimasartan Potassium Trihydrate

非马沙坦钾三水合物

Report date: 2024/12/25 11:58:41
NME

Base Information

Drug NameFimasartan Potassium Trihydrate
Drug Alias NameFimasartanum非马沙坦钾盐Fimasartan非马沙坦Kanarb +[21] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsHypercholesterolemiaEssential HypertensionHypertension +[6] 
Global Approved IndicationsEssential HypertensionHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2010/09/09
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoryung Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaEssential HypertensionHypertension +[4] 
Inactive IndicationsRenal InsufficiencyHepatic Insufficiency

Other Information

ATC CodeC09CA10
Related LinksWikipediaDrugBankKEGG